AstraZeneca and Incyte Corporation announced a new collaboration to evaluate the efficacy and safety of Incyte’s Janus-associated kinase (JAK) 1 inhibitor, INCB39110, in combination with AstraZeneca’s next generation epidermal growth factor receptor (EGFR) inhibitor, Tagrisso®
(osimertinib). The combination will be assessed as a second line
treatment for patients with EGFR mutation-positive non-small cell lung
cancer (NSCLC), who have been treated with a first generation EGFR
tyrosine kinase inhibitor (TKI) and subsequently developed the T790M
resistance mutation.
There is increasing evidence that signalling through the JAK-STAT (signal
transducer and activator of transcription) pathway could be a
contributing factor in resistance to EGFR TKI treatment in patients with
EGFR mutation NSCLC. Blocking both JAK and EGFR activity may therefore
offer an improved targeted treatment benefit in some patients.
Under
the terms of the agreement, AstraZeneca and Incyte will collaborate on a
Phase I/II study, to be conducted by Incyte. The Phase I part of the
trial is expected to establish a recommended dose regimen for the
combination of INCB39110 and Tagrisso, while the Phase
II part of the study will assess the safety and efficacy profile.
Results from the study will be used to determine whether further
clinical development of this combination is warranted.
